APIs and Finished Drug Products
A Resilient and Reliable Supply of Life-Changing Medicines.
Phlow is on a bold mission to produce a reliable supply of the vital medicines necessary for the American population to sustain life and conquer disease.
Filling America’s Medicine Cabinet
Phlow leverages its R&D lab co-located next to the United States Pharmacopeia (USP), its state-of-the-art pharmaceutical manufacturing facilities, and its extensive partnership network to deliver advanced manufacturing solutions, including continuous manufacturing capabilities to provide a reliable and affordable supply of high-quality essential medicines.
Leading the Way to National Health Security
Phlow’s initial focus is to use advanced development and manufacturing methods to reshore critical APIs and reduce dependency on foreign sources. Phlow’s program helps secure our Nation’s essential medicine supply and medical countermeasures by bringing the development and manufacturing of these critical national assets back home. Phlow has end-to-end expertise and capabilities to enable the advanced development and manufacturing of formulation-ready APIs for small molecule essential medicines and novel therapeutics. By providing innovative and stable solutions for onshore API production, Phlow helps the U.S. government protect the health of Americans with domestically-supplied life-changing APIs needed for lifesaving care.
To date, Phlow has delivered more than 2 million doses of essential medicines to the SNS to support the U.S. government’s emergency response capabilities for the health of all Americans.
Putting Pediatric Patients First
Phlow’s finished drug product portfolio focuses on the most vulnerable and shockingly underserved population – pediatric patients. Today in the United States, children’s hospitals struggle to access needed medicines, resulting in compromised patient care, clinician frustration, and increased hospital pharmacy costs and inefficiencies. As a founding member of the Children’s Hospital Coalition (CHC), an unprecedented coalition of best-in-class children’s hospitals, Phlow’s finished drug products bring certainty and resiliency back to the supply chain.
A Sustainable, Domestic Supply of Life-Changing Medicines
The care of America’s children has been unnecessarily impacted by shortages of essential medicines. Phlow’s finished drug portfolio is designed to start addressing this crisis and includes the following:
Neuromuscular Blocker
Rocuronium Bromide Injection
Form: Injection
Strength: 10 mg / mL
NDC Number: 81565-204-02
Diuretic
Furosemide Injection, USP
Form: Injection
Strength: 10 mg / mL
NDC Number: 81565-201-02
Corticosteroid
Dexamethasone Sodium Phosphate Injection, USP
Form: Injection
Strength: 4 mg / mL
NDC Number: 81565-202-02
Anticoagulant
Heparin Sodium Injection, USP
Form: Injection
Strength: 1000 USP units / mL
NDC Number: 81565-203-02